Billionaire Joseph Edelman's Top 10 Long-Term Stock Picks
Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology and healthcare investing.
Iovance Biotherapeutics Inc. (IOVA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | MHR Fund Management Mark Rachesky | 24,417,103 | $180,686,562 | +2% | 19.97% |
| 2. | Perceptive Advisors Joseph Edelman | 22,112,266 | $163,630,768 | -17% | 4.5% |
| 3. | Hood River Capital Management David Swank | 8,991,573 | $66,537,640 | 0.98% | |
| 4. | Soleus Capital Guy Levy | 6,560,000 | $48,544,000 | -24% | 3.05% |
| 5. | Long Focus Capital Management John B. Helmers | 5,132,000 | $37,976,800 | 1.23% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.15 | 250,000 | Director | 320,150 | 2024-02-20 | Filing | |
| $9.15 | 32,000 | Director | 54,000 | 2024-02-20 | Filing | |
| $9.15 | 5,000,000 | Director | 28,067,333 | 2024-02-20 | Filing | |
| $5.56 | 10,000 | Director | 248,633 | 2023-09-18 | Filing | |
| $5.30 | 5,000,000 | Director | 23,067,333 | 2023-09-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.06 | 50,000 | Director | 7,500 | 2024-11-12 | Filing | |
| $8.71 | 20,500 | Director | 100,000 | 2016-08-25 | Filing | |
| $9.10 | 33,500 | Director | 120,500 | 2016-08-24 | Filing | |
| $9.11 | 54,000 | Director | 100,000 | 2016-08-22 | Filing | |
| $7.13 | 16,500 | Director | 154,000 | 2015-09-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 27,534,340 | $203,754,116 | 0% | |
| 2. | 23,476,035 | $173,722,660 | 0% | |
| 3. | 12,249,282 | $90,644,687 | 0% | |
| 4. | 5,871,420 | $43,457,717 | 0% | |
| 5. | 4,750,934 | $35,157,000 | 0.04% |
News See All
10 Firms End 2024 Stronger With Impressive Gains
The Dow Jones Industrial Average dipped by 0.07 percent, the S&P 500 shed 0.43 percent, and the Nasdaq Composite declined by 0.90 percent.
10 Most Promising Cancer Stocks According to Hedge Funds
According to the World Health Organization (WHO), cancer remains one of the leading causes of death globally, responsible for nearly 10 million deaths in 2020, or about one in six deaths worldwide.
12 NASDAQ Stocks with Biggest Upside Potential According to Analysts
Potomac Wealth Advisors president Mark Avallone joined CNBC's 'The Exchange' on November 16 to discuss where he sees investing opportunities following Trump's election.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2024 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2024 Earnings Call Transcript November 7, 2024Iovance Biotherapeutics, Inc. beats earnings expectations.
8 Most Promising Stocks to Buy According to Wall Street Analysts
With only a few days left until the 2024 presidential election, investors are preparing for potential volatility to shake the stock market.
10 Best Biotech Stocks To Buy Under $20
The biotechnology industry is experiencing rapid growth, driven by increasing demand for innovative treatments, technological advancements, and government support.
10 Stocks Under $10 With High Potential
There has been ongoing geopolitical in the Middle East, which escalated recently when Iran launched a series of missiles toward Israel.
10 Worst Cancer Stocks To Buy Now According to Short Sellers
Cancer is the second leading cause of death globally, just behind cardiovascular disease, making oncology one of the largest sectors in the life sciences.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2024 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2024 Earnings Call Transcript August 8, 2024Iovance Biotherapeutics, Inc. beats earnings expectations.
Billionaire Hedge Funds
